standard micro array platform. Researchers are increasingly combining multiple micro array-based applications to evaluate different genomic phenomena. Affymetrix also provides a clear pathway for clinical laboratories and diagnostic partners to advance signatures to the clinic with the only micro array instrument platform that is FDA-approved in the United States and CE-marked in the European Union for in-vitro diagnostic use. Today, more than 20 oncology assays are under development on this platform, encompassing screening through prognosis and monitoring. Through the use of these tools, researchers can achieve a more complete picture of the genesis and evolution of cancer, with the goal of ultimately improving the diagnosis and treatment of the disease. --MORE
